Disease prevention with islet autoantigens.

[16]. Verge CF, Gianani R, Yu L, Pietropaolo M, Smith T, Jackson RA, et al. Late progression to diabetes and evidence for chronic β-cell autoimmunity in identical twins of patients with type I diabetes. Diabetes 1995;44(10):1176-9. Abstract[17]. Scott J. The spontaneously diabetic BB rat: sites of the defects leading to autoimmunity and diabetes mellitus. A review. Curr TopMicrobiol Immunol 1990;156:1-14. Abstract[18]. Greiner DL, Rossini AA, Mordes JP. Translating data from animal models into methods for preventing human autoimmunediabetes mellitus: caveat emptor and primum non nocere. Clin Immunol 2001;100(2):134-43. Abstract[19]. Thomas HE, Kay TW. Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse.Diabetes Metab Res Rev 2000;16(4):251-61. Abstract [20]. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999;5(6):601-4. Citation[21]. Komeda K, Noda M, Terao K, Kuzuya N, Kanazawa M, Kanazawa Y. Establishment of two substrains, diabetes-prone and non-diabetic, from Long-Evans Tokushima Lean (LETL) rats. Endocr J 1998;45(6):737-44. Abstract[22]. Yokoi N, Komeda K, Wang HY, Yano H, Kitada K, Saitoh Y, et al. Cblb is a major susceptibility gene for rat type 1 diabetesmellitus. Nat Genet 2002;31(4):391-4. Abstract[23]. Rajagopalan G, Kudva YC, Flavell RA, David CS. Accelerated diabetes in rat insulin promoter-tumor necrosis factor-alphatransgenic nonobese diabetic mice lacking major histocompatibility class II molecules. Diabetes 2003;52(2):342-7. Abstract[24]. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, et al. Ablation of “tolerance” and induction of diabetes byvirus infection in viral antigen transgenic mice. Cell 1991;65:305-17. Abstract[25]. Moriyama H, Yokono K, Amano K, Nagata M, Hasegawa Y, Okamoto N, et al. Induction of tolerance in murine autoimmunediabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J Immunol1996;157(8):3737-43. Abstract[26]. Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J Clin Invest1999;104(2):189-94. Abstract[27]. Hornum L, Romer J, Markholst H. The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes 2002;51(6):1972-9. Abstract[28]. Ellerman KE, Like AA. Susceptibility to diabetes is widely distributed in normal class IIu haplotype rats. Diabetologia2000;43(7):890-8. Abstract[29]. Jackson R, Rassi N, Crump A, Haynes BF, Eisenbarth GS. The BB diabetic rat. Profound T-cell lymphocytopenia. Diabetes1981;30(10):887-9. Abstract[30]. Fujita T, Yui R, Kusumoto Y, Sherizawa Y, Makino S, Tochino Y. Lymphocytic insulitis in a “non-obese diabetic (NOD)” strainof mice: an immunohistochemical and electron microscope investigation. Biomed Res 1982;3:429-43.[31]. Thebault-Baumont K, Dubois-LaForgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, et al. Acceleration of type 1diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003;111(6):851-7. Abstract[32]. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2003;100(18):10376-81. Abstract[33]. Wong S, Guerder S, Visintin I, Reich E-P, Swenson KE, Flavell RA, et al. Expression of the co-stimulator molecule B7–1 inpancreatic β-cells accelerates diabetes in the NOD mouse. Diabetes 1995;44:326-9. Abstract[34]. Harlan DM, Hengartner H, Huang ML, Kang YH, Abe R, Moreadith RW, et al. Mice expressing both B7–1 and viral glycoproteinon pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyteunresponsiveness. Proc Natl Acad Sci USA 1994;91(8):3137-41. Abstract[35]. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, Stewart TA. Insulin-dependent diabetes mellitus induced in transgenic mice byectopic expression of class II MHC and interferon-gamma. Cell 1988;52(5):773-82. Abstract[36]. von Herrath MG, Wolfe T, Mohrle U, Coon B, Hughes A. Protection from type 1 diabetes in the face of high levels of activatedautoaggressive lymphocytes in a viral transgenic mouse model crossed to the SV129 strain. Diabetes 2001;50(12):2700-8. Abstract[37]. Pechhold K, Patterson NB, Blum C, Fleischacker CL, Boehm BO, Harlan DM. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J Immunol 2001;166(4):2531-9. Abstract[38]. Wen L, Wong FS, Tang J, Chen NY, Altieri M, David C, et al. In vivo evidence for the contribution of human histocompatibilityleukocyte antigen (HLA)-DQ molecules to the development of diabetes. J Exp Med 2000;191(1):97-104. Abstract[39]. Verdaguer J, Yoon J-W, Anderson B, Averill N, Utsugi T, Park B-J, et al. Acceleration of spontaneous diabetes inTCR-β-transgenic nonobese diabetic mice by β-cell cytotoxic CD8+T cells expressing identical endognous TCR-α chains. J Immunol1996;157:4726-35. Abstract[40]. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the {beta} cell antigen targetedby a prevalent population of pathogenic CD8 + T cells in autoimmune diabetes. Proc Natl Acad Sci USA 2003;100(14):8384-8.[38]. Wen L, Wong FS, Tang J, Chen NY, Altieri M, David C, et al. In vivo evidence for the contribution of human histocompatibilityleukocyte antigen (HLA)-DQ molecules to the development of diabetes. J Exp Med 2000;191(1):97-104. Abstract[39]. Verdaguer J, Yoon J-W, Anderson B, Averill N, Utsugi T, Park B-J, et al. Acceleration of spontaneous diabetes inTCR-β-transgenic nonobese diabetic mice by β-cell cytotoxic CD8+T cells expressing identical endognous TCR-α chains. J Immunol1996;157:4726-35. Abstract[40]. Lieberman SM, Evans AM, Han B, Takaki T, Vinnitskaya Y, Caldwell JA, et al. Identification of the {beta} cell antigen targetedby a prevalent population of pathogenic CD8 + T cells in autoimmune diabetes. Proc Natl Acad Sci USA 2003;100(14):8384-8. Abstract[41]. Baud O, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D, et al. Treatment of the immune dysregulation, polyendocrinopathy,[41]. Baud O, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D, et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001;344(23):1758-62. Citation[42]. Greeley SA, Katsumata M, Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, et al. Elimination of maternally transmittedautoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 2002;8(4):399-402. Abstract[43]. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity ofinsulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995;25(4):1056-62. Abstract[44]. Chen W, Bergerot I, Elliott JF, Harrison LC, Abiru N, Eisenbarth GS, et al. Evidence that a peptide spanning the B-C junction ofproinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 2001;167(9):4926-35. Abstract[45]. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, et al. Identification of an MHC class I-restricted autoantigen intype 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999;5(9):1026-31. Abstract[46]. Hutton JC, Eisenbarth GS. A pancreatic {beta}-cell-specific homolog of glucose-6-phosphatase emerges as a major target of cell-mediated autoimmunity in diabetes. Proc Natl Acad Sci USA 2003;100:8626-8. Citation[47]. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003;111(2):217-23. Abstract[48]. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196(12):1645-51. Abstract[49]. Abiru N, Eisenbarth GS. Autoantibodies and autoantigens in type 1 diabetes: role in pathogenesis, prediction and prevention. CanJ Diabetes Care 1999;23(1):59-65.[50]. Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert ED, et al. Early expression and high prevalence of isletautoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: the German BABYDIABstudy. Diabetologia 1999;42(6):671-7. Abstract[51]. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, et al. Latent autoimmune diabetes mellitus in adults(LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med1994;11(3):299-303. Abstract[52]. Ferreira M, Davies SL, Butler M, Scott D, Clark M, Kumar P. Endomysial antibody: is it the best screening test for coeliacdisease? Gut 1992;33:1633-7. Abstract[53]. Spitzenberger F, Pietropaolo S, Verkade P, Habermann B, Lacas-Gervais S, Mziaut H, et al. Islet cell autoantigen of 69 kDa is anarfaptin-related protein associated with the golgi complex of insulinoma INS-1 cells. J Biol Chem 2003;278(28):26166-73. Abstract[54]. Bieg S, Hanlon C, Hampe CS, Benjamin D, Mahoney CP. GAD65 and insulin B chain peptide (9–23) are not primary autoantigens in the type 1 diabetes syndrome of the BB rat. Autoimmunity 1999;31(1):15-24. Abstract[55]. Gottlieb PA, Handler ES, Appel MC, Greiner DL, Mordes JP, Rossini AA. Insulin treatment prevents diabetes mellitus but not thyroiditis in RT 6-depleted diabetes resistant BB/Wor rats. Diabetologia 1991;34(5):296-300. Abstract[56]. von Herrath MG, Dyrberg T, Oldstone MB. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996;98(6):1324-31. Abstract[57]. Judkowski V, Pinilla C, Schroder K, Tucker L, Sarvetnick N, Wilson DB. Identification of MHC class II-restricted peptideligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobesediabetic mice. J Immunol 2001;166(2):908-17. Abstract[58]. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, et al. Oral insulin administration and residual beta-cellfunction in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Lancet 2000;356(9229):545-9. Abstract[59]. Bregenholt S, Wang M, Wolfe T, Hughes A, Baerentzen L, Dyrberg T, et al. The cholera toxin B subunit is a mucosal adjuvantfor oral tolerance induction in type 1 diabetes. Scand J Immunol 2003;57(5):432-8. Abstract[60]. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion proteinprotects against the development of autoimmune diabetes. Nat Biotechnol 1998;16(10):934-8. Abstract[61]. Maron R, Melican NS, Weiner HL. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orallyand nasally-treated NOD mice suppress diabetes. J Autoimmun 1999;12(4):251-8. Abstract[62]. Abiru N, Wegmann D, Kawasaki E, Gottlieb P, Simone E, Eisenbarth GS. Dual overlapping peptides recognized by insulin peptide B:9–23 reactive T cell receptor AV13S3 T cell clones of the NOD mouse. J Autoimmun 2000;14(3):231-7. Abstract[63]. Liu E, Abiru N, Moriyama H, Diao D, Eisenbarth GS. Induction of insulin autoantibodies and protection from diabetes withsubcutaneous insulin B:9-3 peptide without adjuvant. Ann N Y Acad Sci 2002;958:224-7. Abstract[64]. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, et al. Immunological characterization and therapeutic activity ofan altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9–23) peptide.Diabetes 2002;51(7):2126-34. Abstract[65]. Moriyama H, Wen L, Abiru N, Liu E, Yu L, Miao D, et al. Induction and acceleration of insulitis/diabetes in mice with a viralmimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci USA 2002;99(8):5539-44. Abstract[66]. Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice inresponse to insulin self-peptides B:9–23 and B:13–23. J Clin Invest 2002;110(7):1021-7. Abstract[67]. Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, et al. Plasmid vaccination with insulin b chain prevents autoimmunediabetes in nonobese diabetic mice. J Immunol 2001;167(5):2950-5. Abstract[68]. Steptoe RJ, Ritchie JM, Harrison LC. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest 2003;111(9):1357-63. Abstract[69]. Birk OS, Douek DC, Elias D, Takacs K, Dewchand H, Gur SL, et al. A role of Hsp60 in autoimmune diabetes: analysis in a transgenic model. Proc Natl Acad Sci USA 1996;93(3):1032-7. Abstract[70]. Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes innonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000;165(11):6148-55. Abstract[71]. Quintana FJ, Carmi P, Cohen IR. DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. JImmunol 2002;169(10):6030-5. Abstract[71]. Quintana FJ, Carmi P, Cohen IR. DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. JImmunol 2002;169(10):6030-5. Abstract [72]. Bowman M, Atkinson MA. Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia 2002;45(9):1350-1. Citation[73]. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulationwith a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358(9295):1749-53. Abstract[74]. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetesmellitus. N Engl J Med 1989;320(9):550-4. Abstract[75]. Ablamunits V, Elias D, Reshef T, Cohen IR. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 1998;11(1):73-81. Abstract[76]. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of BCG vaccination on new-onset insulin-dependent diabetes mellitus: A randomized clinical study. Diabetes Care 1998;22(10):1703-7.[77]. Tisch R, Wang B, Serreze DV. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmunediabetes at late stages of disease is epitope dependent. J Immunol 1999;163(3):1178-87. Abstract[78]. Tisch R, Liblau RS, Yang X-D, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoingautoimmune diabetes in nonobese diabetic mice. Diabetes 1998;47:894-9. Abstract[79]. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, et al. A disease-associated cellular immune response in type 1diabetics to an immunodominant epitope of insulin. J Clin Invest 2001;107(2):173-80. Abstract[80]. Abiru N, Maniatis AK, Yu L, Miao D, Moriyama H, Wegmann D, et al. Peptide and MHC specific breaking of humoral toleranceto native insulin with the B:9–23 peptide in diabetes prone and normal mice. Diabetes 2001;50:1274-81. Abstract[81]. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003;52(5):1059-65. Citation [82]. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function inpatients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128(7):517-23. Abstract[83]. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, et al. Screening strategies for the identification of multipleantibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003;88(1):103-8. Full Text[84]. Keskinen P, Korhonen S, Kupila A, Veijola R, Erkkila S, Savolainen H, et al. First-phase insulin response in young healthychildren at genetic and immunological risk for Type I diabetes. Diabetologia 2002;45(12):1639-48. Abstract Copyright © 2004 Elsevier Inc. All rights reserved.